STAT
SEPTEMBER 18, 2023
In the wake of growing alarm over the disproportionately high rates of maternal mortality in the U.S., maternal health experts have been pushing for changes — including expanding the midwife workforce. Studies have shown that deliveries attended by midwives tend to have fewer complications and better outcomes, partially because midwife training relies less on medical intervention, leading to fewer C-sections.
PharmaVoice
SEPTEMBER 18, 2023
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 18, 2023
David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned. The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with k
PharmaVoice
SEPTEMBER 18, 2023
The visual inspection of injectable drug product has been a regulatory requirement since 1936, however, successful implementation of the standard has been challenging for many organizations.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
SEPTEMBER 18, 2023
The era of rampant, unconsented, and unregulated online data collection may finally be winding down for consumer health data. But the advances in consumer privacy have not yet fully reached the millions of people with health information related to their drug use, substance use disorder treatment, or recovery. In July, two key agencies for consumer health privacy, the Department of Health and Human Services and the Federal Trade Commission, sent letters to 130
BioPharma Dive
SEPTEMBER 18, 2023
Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID and flu.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
SEPTEMBER 18, 2023
The treatment is the first oral GPCR receptor antagonist class recommended for NHS use - News - PharmaTimes
STAT
SEPTEMBER 18, 2023
Medicare plans to pay more for a type of cardiac rehabilitation that takes place in certain outpatient clinics owned by hospitals. Medicare has admitted it is doing so due to an error in reading federal law, but it also goes against the grain of the current environment, where support for site-neutral payments has never been higher. Some members of Congress and health care experts are pushing for a system that would not pay hospital outpatient departments more for identical services that are prov
Pharma Times
SEPTEMBER 18, 2023
The updated vaccines more closely target current circulating variants - News - PharmaTimes
STAT
SEPTEMBER 18, 2023
Good morning, everyone, and welcome to another working week. We hope the weekend respite was restful and invigorating because now that familiar routine of meetings and deadlines and what-not has returned. As you might expect, we are coping by quaffing a few cups of welcome stimulation — our flavor today is southern pecan — and, as always, we invite you to join us.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
SEPTEMBER 18, 2023
The article “Maximizing the Value of Drug Patents Before Losing Exclusivity” discusses strategies for biomedical companies to maximize the value of their drug patents before the exclusivity period expires. In… The post Maximizing Drug Patents’ Value: Strategies for Biomedical Companies appeared first on DrugPatentWatch - Make Better Decisions.
World Pharma News
SEPTEMBER 18, 2023
Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Ba
The Pharmacist
SEPTEMBER 18, 2023
NICE has approved rimegepant as the first treatment for acute migraine, in draft guidance published this month. Around 13,000 could benefit from rimegepant (Vydura, Pfizer), said NICE after signing off its use in adults who have tried at least two triptans but they did not work well enough. It can also be used for those […] The post NICE to recommend rimegepant as first acute migraine treatment appeared first on The Pharmacist.
BioPharma Dive
SEPTEMBER 18, 2023
With the rise of ChatGPT and artificial intelligence (AI), there are many ways the clinical staffing industry can use AI advantageously while removing the stigma that the rise of technology can be dehumanizing.
Express Pharma
SEPTEMBER 18, 2023
Biocon has approved the appointment of Peter Bains as the Group CEO, with effect from September 18, 2023. He will be reporting directly to Biocon Group Chairperson, Kiran Mazumdar-Shaw. Bains has accordingly stepped down from his role on the Biocon Board as an Independent Director with immediate effect, to assume this strategic executive responsibility.
European Pharmaceutical Review
SEPTEMBER 18, 2023
The Cell and Gene Therapy Catapult (CGT Catapult) , supported by Scotland’s national economic development agency, Scottish Enterprise, has launched a new cooperative network to foster collaboration and increase knowledge sharing across the Advanced Therapy Medicinal Products (ATMP) industry in Scotland. Events, as well as talks from industry leaders and networking opportunities, will be coordinated by a new ‘Scottish Advanced Therapy Medicinal Products (ATMP) and Vaccines Network’ to aid individ
Pharmaceutical Technology
SEPTEMBER 18, 2023
Embattled biotech giant Illumina has led series A funding into genomics mapping company Broken String Biosciences.
Outsourcing Pharma
SEPTEMBER 18, 2023
The French-U.S. company Novadiscovery has hailed a âwatershed moment for clinical trial designâ as its trial simulation tool successfully predicted the outcome of a phase 3 oncology trial run by AstraZeneca.
Express Pharma
SEPTEMBER 18, 2023
Dassault Systèmes introduced “Emma Twin,” an avatar designed to raise awareness of the key role that virtual twins have in advancing healthcare and the innovations that are shaping the future of medicine. Through a social media programme, Emma Twin will share stories explaining how the virtual twin of her body was created from anonymous health data to be used for an infinite number of tests that give doctors and researchers a profound understanding of diseases and the effects of new and improved
Pharmaceutical Technology
SEPTEMBER 18, 2023
The FDA released a draft guidance giving advice on the correct labelling of biosimilar and interchangeable biosimilar products.
BioPharma Dive
SEPTEMBER 18, 2023
Three years after gaining European approval, Libmeldy is now under U.S. review with a deadline set for March.
Pharmaceutical Technology
SEPTEMBER 18, 2023
Despite major shifts in the IBD landscape, most approaches that go beyond targeting inflammation remain in the earlier stages of development.
European Pharmaceutical Review
SEPTEMBER 18, 2023
The first and only treatment for anaemic patients with myelofibrosis has been approved by the US Food and Drug Administration (FDA). Ojjaara (momelotinib) is indicated for intermediate or high-risk myelofibrosis, a blood cancer, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
The Pharmacist
SEPTEMBER 18, 2023
The patient group directions (PGDs) that will enable community pharmacists in England to provide a common conditions service are currently being worked through by government and NHS England (NHSE), Community Pharmacy England (CPE) chief executive Janet Morrison has confirmed. The service will utilise seven PGDs to allow community pharmacists to treat – including with antibiotics […] The post Pharmacy First PGDs ‘being worked through’ appeared first on The Pharmacist.
European Pharmaceutical Review
SEPTEMBER 18, 2023
The European Medicines Agency (EMA)’s human medicines committee (CHMP) recommended nine new medicines for approval during its meeting in September 2023. The committee recommended granting a marketing authorisation for Ebglyss (lebrikizumab). This medicine is indicated for treating moderate-to-severe atopic dermatitis in adults and adolescents. To treat glioma, a type of brain tumour, the CHMP gave a positive opinion for Finlee (dabrafenib).
Outsourcing Pharma
SEPTEMBER 18, 2023
The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia.
National Association of Boards of Pharmacy
SEPTEMBER 18, 2023
The United States is home to one of the most secure drug supply chains in the world, but criminals still find pathways to buy and sell prescription drugs—including controlled substances—often using websites and social media platforms to do so. We compiled information from experts about how criminals use online platforms to sell these drugs illegally and information to help you educate patients on protecting themselves and their loved ones.
Outsourcing Pharma
SEPTEMBER 18, 2023
The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around â330 million ($352 million).
BioPharma Dive
SEPTEMBER 18, 2023
The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.
pharmaphorum
SEPTEMBER 18, 2023
Allis.health – a digital health analyst in your pocket Phil.
Drug Channels
SEPTEMBER 18, 2023
Informa Connect’s Patient Support Services Congress November 7-9, 2023 | The Inn at Penn, Philadelphia, PA [link] Exclusive Offer – Be sure to use your exclusive promo code 23DC10 to save 10% off* of your registration. The Patient Support Services Congress is a dialogue-driven meeting that arms the industry with innovative trends and next-generation approaches to patient services for optimal performance.
pharmaphorum
SEPTEMBER 18, 2023
US researchers start trials of universal flu vaccine Phil.
BioPharma Dive
SEPTEMBER 18, 2023
As integrated evidence generation takes center stage for driving evidence-based decision making across the product life cycle, automated registries just might be the linchpin that pulls it all together.
Drug Patent Watch
SEPTEMBER 18, 2023
Annual Drug Patent Expirations for ACTOPLUS+MET+XR Actoplus Met Xr is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are five patents protecting this drug… The post New patent expiration for Takeda Pharms drug ACTOPLUS MET XR appeared first on DrugPatentWatch - Make Better Decisions.
Board Vitals - Pharmacist
SEPTEMBER 18, 2023
In today’s fast-paced academic world, where time is often our most valuable resource, it’s crucial to study smarter, not harder. BoardVitals’ new Risk Assessment Reporting offers an innovative way to make the most of your study time. This AI-powered performance metric makes it simple to pinpoint your highest risk subjects so you can focus your time on areas you need the most work.
Expert insights. Personalized for you.
363 
Let's personalize your content